CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) had its target price lifted by Citigroup from $53.00 to $83.00 in a report issued on Tuesday morning, The Fly reports. The firm currently has a neutral rating on the stock.
Several other equities analysts have also recently issued reports on the stock. Barclays decreased their price target on shares of CRISPR Therapeutics from $107.00 to $99.00 in a research report on Tuesday, May 10th. Oppenheimer reduced their price objective on shares of CRISPR Therapeutics from $150.00 to $122.00 and set an outperform rating on the stock in a research note on Thursday, June 23rd. The Goldman Sachs Group reduced their price objective on shares of CRISPR Therapeutics from $52.00 to $46.00 and set a neutral rating on the stock in a research note on Tuesday, May 24th. Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $168.00 to $164.00 and set a buy rating on the stock in a research note on Wednesday, June 22nd. Finally, BMO Capital Markets initiated coverage on shares of CRISPR Therapeutics in a research note on Thursday, June 16th. They issued an outperform rating and a $98.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Moderate Buy and an average target price of $116.19.
CRISPR Therapeutics Stock Performance
Shares of NASDAQ CRSP opened at $76.34 on Tuesday. CRISPR Therapeutics has a 52-week low of $42.51 and a 52-week high of $142.64. The firm has a 50 day moving average price of $69.22 and a two-hundred day moving average price of $62.80. The stock has a market cap of $5.91 billion, a P/E ratio of 21.15 and a beta of 1.93.
Insider Buying and Selling at CRISPR Therapeutics
In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of $75.91, for a total value of $1,897,750.00. Following the transaction, the chief executive officer now directly owns 290,279 shares of the company’s stock, valued at $22,035,078.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.70% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of CRISPR Therapeutics in the first quarter valued at about $289,982,000. Nikko Asset Management Americas Inc. raised its holdings in shares of CRISPR Therapeutics by 31.3% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 4,319,471 shares of the company’s stock valued at $330,526,000 after purchasing an additional 1,029,955 shares during the last quarter. BlackRock Inc. raised its holdings in shares of CRISPR Therapeutics by 79.2% in the first quarter. BlackRock Inc. now owns 2,278,774 shares of the company’s stock valued at $143,038,000 after purchasing an additional 1,007,246 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of CRISPR Therapeutics by 261.4% in the first quarter. Vanguard Group Inc. now owns 1,217,289 shares of the company’s stock valued at $76,410,000 after purchasing an additional 880,463 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $43,865,000. 56.12% of the stock is owned by institutional investors.
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
- Get a free copy of the StockNews.com research report on CRISPR Therapeutics (CRSP)
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.